Business Wire

SMITH-&-NEPHEW

30.8.2016 10:04:52 CEST | Business Wire | Press release

Share
Smith & Nephew: Evidence and Expert Opinion Highlights Clinical and Aesthetic Benefits of PICO◊ Single-Use Negative Pressure Wound Therapy in Mammoplasty and Oncological Breast Reconstructive Surgery

Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces how expert opinion around the world continues to build around the use of PICO, a novel single use negative pressure wound therapy (NPWT) in avoiding post-operative wound complications. At a recent meeting hosted by Smith & Nephew in Paris, over 160 European experts in plastic and onco-plastic surgery met to share the latest evidenced based best practice around the use of PICO, in the prevention of incisional complications following breast surgery.

Incisional complications and delayed healing are not uncommon following breast surgery and can cause avoidable hospital readmissions or increased lengths of stay, which has implications for both the healthcare system and patient outcomes. Delayed healing is a particular issue in post mastectomy reconstruction where the risk of a surgical complication has been found to be four times higher than in non-oncology breast surgery1 , and where any delay to adjunctive treatment such as radiotherapy is to be avoided.

Preventing a wound complication following a mastectomy or lumpectomy is crucial. Even a minor complication can delay radiotherapy or chemotherapy, and can potentially have devastating consequences. Predictable wound healing is vital for this reason but to also save the patient from experiencing psychological distress if treatment is postponed ” says Jennifer Rusby, Consultant Oncoplastic Surgeon, Royal Marsden, London, UK.

With regards to breast reduction surgery, other issues were raised with regards to wound care and post operative issues including scar quality. A multicentre-study2 involving 200 bilateral breast reduction patients was presented, which showed significantly fewer wound healing complications for PICO compared to standard care (p=0.004), and a 38% relative reduction in surgical dehiscence by day 21 (a surgical complication in which the wound ruptures along the surgical suture line) from 52 patients (26.4%) to 32 patients (16.2%) (p<0.001). The study also evaluated the scar quality at 42 and 90 days post surgery. PICO showed significantly better scar quality at each time point (p<0.001).

Clinical complications including surgical site infections following breast surgery were also identified as significantly higher amongst patients with a high BMI3 , impacting on both clinical and aesthetic outcomes, but also on the hospital’s resources due to re-admissions and further post-operative care.

Professor Laurent Lantieri, Chief of Department of Plastics and Reconstruction surgery, European Hospital Georges Pompidou, Paris, chaired the meeting, and explained further:

"It is very important to bring some of the most experienced and innovative surgeons together at meetings such as this; to share first-hand ideas which you cannot get from reading a journal article or attending large scientific conferences. It is these interactive meetings that are important for the future of education. If I give you one idea and you give me one idea we both have two ideas, and by exchanging these ideas we can improve our knowledge and even inform future practice.”

The Plastic Surgery Expert Meeting hosted by Smith & Nephew is one of a series of six meetings happening during 2016, including the use of NPWT across specialities such as orthopaedic, cardiothoracic and vascular surgery and obstetrics and gynaecology.

For images and video footage from the meeting please visit:

http://www.smith-nephew.com/news-and-media/media-releases/news/expert-opinion-highlights-clinical-and-aesthetic-benefits-of-pico/

- ends -

1 Olsen, M. A., Lefta, M., Dietz, J. R., Brandt, K. E., Aft, R., Matthews, R., & Fraser, V. J. 2008. Risk factors for surgical site infection after major breast operation. J Am Coll Surg 2008;207:326–335

2 Galiano R, Djohan R, Shin J, Hudson D, Van der Hulst, Beugels J, Duteille F, Huddleston E, Cockwill J, Megginson S The effects of a single use canister-free Negative Pressure Wound Therapy (NPWT) System* on the prevention of postsurgical wound complications in patients undergoing bilateral breast reduction surgery (First presented at The British Association of Aesthetic Plastic Surgeons (BAAP’s) 30th Annual Scientific Meeting, London, September 2014)

3 Davis, G. B., Peric, M., Chan, L. S., Wong, A. K., & Sener, S. F. 2013. Identifying risk factors for surgical site infections in mastectomy patients using the NSQIP database. The American Journal of Surgery, 2013 205(2) 194–199

Contact:

For Smith & Nephew
Rachel Cunningham
02089955832
rachelg@roadcommunications.co.uk

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SES Launches Cash Tender Offer11.3.2026 13:25:00 CET | Press release

THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE MARKET ABUSE REGULATION (EU) 596/2014. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN, OR AT ANY ADDRESS IN, THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE UNITED STATES) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT)) OR IN OR INTO ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT (SEE “OFFER AND DISTRIBUTION RESTRICTIONS” BELOW). SES (the “Offeror”) announces today that it is inviting holders of its outstanding €625,000,000 Deeply Subordinated Fixed Rate Re

Thredd and Cross River to Accelerate Expansion into the US Market for Global Fintechs11.3.2026 13:01:00 CET | Press release

B4B Payments scales U.S. operations through collaboration Thredd, the AI-first issuer processing platform, today announced a strategic alliance with Cross River Bank (“Cross River”), a technology infrastructure provider that offers embedded financial solutions. The relationship is designed to accelerate the entry of international fintechs into the United States. This collaboration leverages Thredd’s global expertise and technology stack with Cross River’s proprietary core infrastructure, established market leadership and regulatory expertise, creating a seamless pathway for innovative payment solutions to launch and scale in the U.S. As part of this agreement, Thredd becomes one of Cross River’s select strategic processing partners outside of the bank’s own stack. The arrangement enables Thredd to introduce a curated pipeline of high-potential fintech clients from various geographic regions*.1 In turn, Thredd’s clients benefit from Cross River’s proven ability to deliver compliant, sca

SLB Provides Update on Middle East Operations and First Quarter Outlook11.3.2026 13:00:00 CET | Press release

SLB (NYSE: SLB) continues to closely monitor the unfolding situation in the Middle East and adapt its operations. The safety and security of SLB’s employees is the highest priority, and the company has activated local and regional crisis response teams that are meeting daily. Travel to and transit through the region have been suspended, and the company has begun to demobilize operations in a few countries in response to customer actions to safeguard personnel and facilities. These measures will continue as long as necessary until the environment in the region has stabilized. SLB is working closely with local authorities and its customers to monitor the situation and will begin a phased resumption of full activity as conditions allow. SLB revenue for the first quarter will be lower than expected, and the company expects to incur additional costs resulting in an impact of approximately 6-9 cents of earnings per diluted share for the first quarter. Given the dynamic nature of the environm

IQM Delivers Fourth Quantum Computer in Finland, Operational at Aalto University11.3.2026 11:32:00 CET | Press release

This is the fourth quantum computer deployed by IQM to customers in Finland to boost research and education in a growing ecosystem. The system named Aalto Q20 quantum computer is online at Aalto University and will enable students and scientists a unique first-hand access to a world-class quantum computer. The university will use the quantum computer to perform scientific experiments on advanced level and to support national and European quantum research activities. IQM Quantum Computers, the global leader in deployed on-premises, full-stack superconducting quantum computers, today announced the launch of Aalto Q20 quantum computer in Finland, reinforcing its commercial leadership in the quantum industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311215316/en/ Ribbon cutting of the Aalto Q20 quantum computer delivered by IQM. The 20-qubit system, which is operational at Aalto University, is the fourth quantum compute

Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site11.3.2026 11:00:00 CET | Press release

Highlights Agreement builds on existing Chiesi-Bespak collaboration, reinforcing a trusted relationship as Chiesi works to evolve a portfolio of extrafine formulation Carbon Minimal Inhalers1, ensuring patients retain continuity of care while reducing carbon emissionsBespak’s leadership in low-GWP propellant inhaler manufacturing along with significant expansion at its Holmes Chapel site strengthens Chiesi’s global supply chain resiliencePartnership aligns with the science-based climate commitments of both companies Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership, increasing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel site to support the next phase of Chiesi’s Carbon Minimal Inhaler (CMI) program. This press release features multi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye